# Fennec Pharmaceuticals Inc.: financial statements, quarterly

FENC · Nasdaq · CIK 1211583 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fenc.md) · [Financials](/companies/fenc/financials.md) · [Filings](/companies/fenc/filings.md) · [Insiders](/companies/fenc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fenc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.5](/filings/0001558370-24-015068.md) | [9.7 d](/filings/0001558370-25-003710.md) | [25.4](/filings/0001558370-25-007748.md) | [7.3](/filings/0001558370-25-011552.md) | [7.0](/filings/0001104659-25-111260.md) | [7.9 d](/filings/0001104659-26-036182.md) | [8.8](/filings/0001104659-26-061213.md) | [9.7](/filings/0001104659-26-095884.md) | [12.5](/filings/0001104659-25-111260.md) | [13.8 d](/filings/0001104659-26-036182.md) | [15.1](/filings/0001104659-26-061213.md) | [17.9](/filings/0001104659-26-095884.md) |
| Cost of revenue | $m | [0.3](/filings/0001558370-23-018614.md) | [0.7 d](/filings/0001558370-24-004383.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [6.2](/filings/0001558370-23-018614.md) | [9.1 d](/filings/0001558370-24-004383.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [0.0](/filings/0001558370-24-015068.md) | [0.0 d](/filings/0001558370-25-003710.md) | [0.0](/filings/0001558370-25-007748.md) | [0.2](/filings/0001558370-25-011552.md) | [0.1](/filings/0001104659-25-111260.md) | [0.1 d](/filings/0001104659-26-036182.md) | [0.1](/filings/0001104659-26-061213.md) | [0.1](/filings/0001104659-26-095884.md) | [0.0](/filings/0001104659-25-111260.md) | [0.0 d](/filings/0001104659-26-036182.md) | [0.0](/filings/0001104659-26-061213.md) | [0.1](/filings/0001104659-26-095884.md) |
| Operating income | $m | [(1.0)](/filings/0001558370-24-015068.md) | [(1.8) d](/filings/0001558370-25-003710.md) | [13.7](/filings/0001558370-25-007748.md) | [(5.0)](/filings/0001558370-25-011552.md) | [(5.2)](/filings/0001104659-25-111260.md) | [(0.9) d](/filings/0001104659-26-036182.md) | [(0.8)](/filings/0001104659-26-061213.md) | [(2.7)](/filings/0001104659-26-095884.md) | [(0.2)](/filings/0001104659-25-111260.md) | [(2.6) d](/filings/0001104659-26-036182.md) | [(0.1)](/filings/0001104659-26-061213.md) | [1.7](/filings/0001104659-26-095884.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001104659-26-095884.md) | [0.0 d](/filings/0001104659-26-095884.md) | not reported | not reported | not reported | [0.0](/filings/0001104659-26-095884.md) |
| Net income | $m | [(1.9)](/filings/0001558370-24-015068.md) | [(2.7) d](/filings/0001558370-25-003710.md) | [12.8](/filings/0001104659-25-111260.md) | [(5.6)](/filings/0001104659-25-111260.md) | [(5.7)](/filings/0001104659-25-111260.md) | [(2.0) d](/filings/0001104659-26-036182.md) | [(1.2)](/filings/0001104659-26-095884.md) | [(3.2)](/filings/0001104659-26-095884.md) | [(0.6)](/filings/0001104659-25-111260.md) | [(4.8) d](/filings/0001104659-26-036182.md) | [0.2](/filings/0001104659-26-095884.md) | [2.0](/filings/0001104659-26-095884.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0001558370-24-015068.md) | not reported | [0.41](/filings/0001558370-25-007748.md) | [(0.20)](/filings/0001558370-25-011552.md) | [(0.21)](/filings/0001104659-25-111260.md) | not reported | [(0.04)](/filings/0001104659-26-061213.md) | [(0.11)](/filings/0001104659-26-095884.md) | [(0.02)](/filings/0001104659-25-111260.md) | not reported | [0.01](/filings/0001104659-26-061213.md) | [0.05](/filings/0001104659-26-095884.md) |
| Basic EPS | $ per share | [(0.07)](/filings/0001558370-24-015068.md) | not reported | [0.47](/filings/0001558370-25-007748.md) | [(0.20)](/filings/0001558370-25-011552.md) | [(0.21)](/filings/0001104659-25-111260.md) | not reported | [(0.04)](/filings/0001104659-26-061213.md) | [(0.11)](/filings/0001104659-26-095884.md) | [(0.02)](/filings/0001104659-25-111260.md) | not reported | [0.01](/filings/0001104659-26-061213.md) | [0.06](/filings/0001104659-26-095884.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [12.4](/filings/0001558370-23-018614.md) | [13.3](/filings/0001558370-25-003710.md) | [51.2](/filings/0001558370-24-008162.md) | [43.1](/filings/0001558370-24-012074.md) | [40.3](/filings/0001558370-24-015068.md) | [26.6](/filings/0001104659-26-036182.md) | [22.7](/filings/0001558370-25-007748.md) | [18.7](/filings/0001558370-25-011552.md) | [21.9](/filings/0001104659-25-111260.md) | [36.8](/filings/0001104659-26-095884.md) | [40.2](/filings/0001104659-26-061213.md) | [41.2](/filings/0001104659-26-095884.md) |
| Current assets | $m | [19.9](/filings/0001558370-24-004383.md) | [26.9](/filings/0001558370-25-003710.md) | [68.2](/filings/0001558370-24-008162.md) | [62.2](/filings/0001558370-24-012074.md) | [58.0](/filings/0001558370-24-015068.md) | [44.1](/filings/0001104659-26-036182.md) | [43.0](/filings/0001558370-25-007748.md) | [40.8](/filings/0001558370-25-011552.md) | [46.1](/filings/0001104659-25-111260.md) | [67.0](/filings/0001104659-26-095884.md) | [66.9](/filings/0001104659-26-061213.md) | [72.5](/filings/0001104659-26-095884.md) |
| Total assets | $m | [20.0](/filings/0001558370-24-004383.md) | [26.9](/filings/0001558370-25-003710.md) | [69.2](/filings/0001558370-24-008162.md) | [63.2](/filings/0001558370-24-012074.md) | [58.9](/filings/0001558370-24-015068.md) | [44.9](/filings/0001104659-26-036182.md) | [46.4](/filings/0001558370-25-007748.md) | [44.9](/filings/0001558370-25-011552.md) | [49.3](/filings/0001104659-25-111260.md) | [70.6](/filings/0001104659-26-095884.md) | [71.8](/filings/0001104659-26-061213.md) | [75.8](/filings/0001104659-26-095884.md) |
| Current liabilities | $m | [3.9](/filings/0001558370-23-018614.md) | [7.6](/filings/0001558370-25-003710.md) | [9.8](/filings/0001558370-24-008162.md) | [7.7](/filings/0001558370-24-012074.md) | [7.4](/filings/0001558370-24-015068.md) | [6.9](/filings/0001104659-26-036182.md) | [8.4](/filings/0001558370-25-007748.md) | [8.4](/filings/0001558370-25-011552.md) | [9.8](/filings/0001104659-25-111260.md) | [10.5](/filings/0001104659-26-095884.md) | [9.6](/filings/0001104659-26-061213.md) | [12.4](/filings/0001104659-26-095884.md) |
| Total liabilities | $m | [29.6](/filings/0001558370-23-018614.md) | [38.5](/filings/0001558370-25-003710.md) | [66.2](/filings/0001558370-24-008162.md) | [64.5](/filings/0001558370-24-012074.md) | [64.1](/filings/0001558370-24-015068.md) | [50.8](/filings/0001104659-26-036182.md) | [52.3](/filings/0001558370-25-007748.md) | [52.3](/filings/0001558370-25-011552.md) | [53.8](/filings/0001104659-25-111260.md) | [35.1](/filings/0001104659-26-095884.md) | [34.1](/filings/0001104659-26-061213.md) | [33.3](/filings/0001104659-26-095884.md) |
| Long-term debt | $m | [25.6](/filings/0001558370-23-018614.md) | [30.9](/filings/0001558370-24-004383.md) | [31.3](/filings/0001558370-24-008162.md) | [31.8](/filings/0001558370-24-012074.md) | [32.1](/filings/0001558370-24-015068.md) | [19.3](/filings/0001558370-25-003710.md) | [19.4](/filings/0001558370-25-007748.md) | [19.4](/filings/0001558370-25-011552.md) | [19.4](/filings/0001104659-25-111260.md) | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(10.5)](/filings/0001558370-24-015068.md) | [(11.6)](/filings/0001104659-26-036182.md) | [3.0](/filings/0001104659-25-111260.md) | [(1.4)](/filings/0001104659-25-111260.md) | [(5.2)](/filings/0001104659-25-111260.md) | [(5.9)](/filings/0001104659-26-095884.md) | [(5.9)](/filings/0001104659-26-095884.md) | [(7.5)](/filings/0001104659-26-095884.md) | [(4.5)](/filings/0001104659-25-111260.md) | [35.5](/filings/0001104659-26-095884.md) | [37.7](/filings/0001104659-26-095884.md) | [42.4](/filings/0001104659-26-095884.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.8) d](/filings/0001558370-24-015068.md) | [(4.9) d](/filings/0001558370-25-003710.md) | [39.0](/filings/0001558370-25-007748.md) | [(8.4) d](/filings/0001558370-25-011552.md) | [(2.2) d](/filings/0001104659-25-111260.md) | [(1.5) d](/filings/0001104659-26-036182.md) | [(4.3)](/filings/0001104659-26-061213.md) | [(3.7) d](/filings/0001104659-26-095884.md) | [1.5 d](/filings/0001104659-25-111260.md) | [(6.0) d](/filings/0001104659-26-036182.md) | [2.4](/filings/0001104659-26-061213.md) | [0.1 d](/filings/0001104659-26-095884.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [26.1](/filings/0001558370-23-018614.md) | [26.6](/filings/0001558370-24-008162.md) | [26.5](/filings/0001558370-24-012074.md) | [26.6](/filings/0001558370-24-015068.md) | [31.1](/filings/0001558370-25-007748.md) | [27.3](/filings/0001558370-25-011552.md) | [27.4](/filings/0001104659-25-111260.md) | [27.6](/filings/0001104659-26-061213.md) | [27.7](/filings/0001104659-26-095884.md) | [27.9](/filings/0001104659-25-111260.md) | [35.5](/filings/0001104659-26-061213.md) | [36.4](/filings/0001104659-26-095884.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 35,067,159 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001104659-26-095884.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.